A total of 2,109,050 Cubans have already completed the three-dose vaccination schedule of one of the vaccine candidates developed in the country against COVID-19.

Cuba studied 43,808 samples of COVID 19, resulting in 6,057 positive ones. The country accumulates 5, 950,808 samples taken and 294,449 positive.

The Abdala vaccine, obtained by the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym), will benefit pregnant women in the second and third trimester of gestation and infants, as well as people allergic to thiomersal in the coming months.

In the midst of an epidemiological context marked by the circulation of new strains in the country, there is evidence of an increase in the severity of COVID-19 in infected patients.

An agreement between the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym) and the University of Havana (UH) will allow the creation of a joint laboratory in Nanobiomedicine, for the execution of innovative projects linked to the design and production of drugs.

The Cuban Finlay Vaccine Institute highlighted the high safety level proven by clinical trials with the COVID-19 candidate vaccine Soberana 02 in Cuban children.

Two million 108 thousand 739 citizens in Cuba have already received all three doses of the locally developed COVID-19 vaccines which have immunized them against the virus.

A study carried out by professors from the Psychology Faculty of the University of Havana and supported by the United Nations Children's Fund ( UNICEF) office in Cuba revealed that due to the confinement in homes as a protection measure against COVID-19, children and adolescents on the island showed symptoms of psychological discomfort.

The application of the vaccine candidate Soberana Plus to 253 health workers who suffered from COVID-19, shows the progress of this intervention that covers 308 of those people in Villa Clara, as a guarantee for the protection of health workers in Cuba.

Cuba studied 44,310 samples for COVID 19, resulting in 6,505 positive ones. The country accumulates 5, 907,000,000 samples taken and 288,392 positive.

The statistical analysis of a larger volume of data revealed other favorable results of efficacy of the Cuban vaccine Abdala against symptomatic COVID-19, informed today Dr. Francisco Hernandez Bernal, chief monitor of the clinical studies with this immunogen of the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym).

The immunization against COVID-19 with the Abdala vaccine, developed by the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym), is expected to be completed later this month in Havana, said Dr. Marta Ayala Avila, director of that institution.

The vaccine candidate Mambisa enters the global list of nasal immunogens that advance to the clinical trial phase, according to Gerardo Guillen Nieto, Director of Biomedical Research of the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym).

AICA Laboratories received the authorization to start a clinical trial to evaluate the safety and antiviral effect of the anti-SARS-Cov-2 gamma globulin in severe adult patients with COVID-19.